Stratos Wealth Partners LTD. Has $372,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stratos Wealth Partners LTD. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 423 shares of the biopharmaceutical company’s stock after selling 43 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Regeneron Pharmaceuticals were worth $372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Ronald Blue Trust Inc. grew its position in Regeneron Pharmaceuticals by 18.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 12 shares during the period. Drive Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 12 shares during the period. Cassia Capital Partners LLC grew its position in Regeneron Pharmaceuticals by 2.3% in the 3rd quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 13 shares during the period. Sutton Wealth Advisors Inc. grew its position in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock valued at $13,124,641 in the last quarter. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of Regeneron Pharmaceuticals stock opened at $904.70 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market capitalization of $99.30 billion, a P/E ratio of 26.03, a P/E/G ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The stock’s 50-day simple moving average is $957.56 and its 200 day simple moving average is $889.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $10.96 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Analysts Set New Price Targets

REGN has been the topic of several recent analyst reports. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $970.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.